|Articles|July 23, 2013

Pharma PE Ebook

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

How will DTC Programs Impact PBMs?

ByMike Hollan,Chris O'Dell

October 28th 2025

Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age

ByNicholas Jacobus

October 27th 2025

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales

ByNicholas Jacobus

October 27th 2025

GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate

ByNicholas Jacobus

October 27th 2025

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences

ByNicholas Jacobus

October 27th 2025

Pharma PE Ebook

Newsletter

Related Content

How will DTC Programs Impact PBMs?

Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales

GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences

Trending on PharmExec

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales

Study Claims Ozempic Lowers Biological Age

GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate

How will DTC Programs Impact PBMs?

Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age